CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
Email ID: complianceofficer@concordbiotech.com

September 18, 2026

To The Manager, Listing Department **National Stock Exchange of India Limited** Plot No. C/1 G Block, Bandra-Kurla Complex, Bandra (East), Mumbai -400 051 Symbol: CONCORDBIO	To General Manager, Listing Department **BSE Limited** Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code: 543960

Sub.: Intimation of Outcome of U.S. Food and Drug Administration (USFDA) Inspection at Unit II – Valthera Formulation Facility of the Company

Dear Sir / Madam,

Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, this is to notify that the USFDA conducted Inspection at the Company's formulation facility located at Unit II–297–298/2p, At. Valthera., Tal. Dholka, Dist., Ahmedabad–382225, Gujarat, India.

The inspection has been successfully concluded with one minor procedural observation which is not related to GMP. The Company will submit a comprehensive response to the observation within the stipulated timeline.

The requisite details of terms of the provisions of Regulation 30 read with Schedule III and SEBI Master Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024 read with Master Circular no. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 issued on July 11, 2023 and last updated on January 30, 2026 are enclosed herewith.

This is for your information and records.

Thanking you.

For Concord Biotech Limited

Paritosh Trivedi
Digitally signed by Paritosh Trivedi
Date: 2026.09.18 10:10:43 +05'30'

Paritosh Trivedi
Company Secretary & Compliance Officer
ACS 63623

CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-380015, Gujarat.
Phone : +91-79-68138700 Fax : +91-79-68138725 CIN No.: L24230GJ1984PLC007440
Email ID: complianceofficer@concordbiotech.com

Sr. No.	Particulars	Details
a)	Name of the regulatory or licensing authority	U. S. Food & Drug Administration (USFDA)
b)	Brief details of the approval/license obtained/ withdrawn/ surrendered	USFDA has conducted an Inspection at Unit – II formulation facility located at Valthera., Tal. Dholka, Dist., Ahmedabad–382225. The inspection was successfully completed on September 18, 2026 and at the conclusion, the USFDA has issued one minor observation which is procedural in nature and not related to GMP.
c)	impact/relevance of such approval/license to the listed entity	We do not expect this development to have any material impact on the current business operations or existing supplies from this facility.
d)	withdrawal/cancellation or suspension of licence/approval by the regulatory or licensing authority, with reasons for such action, estimated impact (monetary or otherwise) on the listed entity and penalty, if any	Not Applicable
e)	period for which such approval/license is/was valid	Not Applicable
f)	the actual impact (monetary or otherwise) along with corrective actions taken by the listed entity pursuant to the withdrawal, cancellation or suspension of the key license/ approval.	Not Applicable